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ABSTRACT  24 
Available medical treatments for symptomatic endometriosis act by inhibiting ovulation, reducing 25 
serum oestradiol levels, and suppressing uterine blood flows. To this aim, several drugs can be used, 26 
with a similar magnitude of effect, in term of pain relief, independently of the mechanism of action. 27 
Conversely, safety, tolerability, and cost differ. Medications for endometriosis can be categorised into 28 
low-cost drugs, including OCs and most progestogens, and high cost drugs, including dienogest and 29 
GnRH agonists. As the individual response to different drugs is variable, a stepwise approach is 30 
suggested, starting with OCs or low-cost progestogens, and stepping up to high-cost drugs only in case 31 
of inefficacy or intolerance. Oral contraceptives may be used in women with dysmenorrhoea as their 32 
main complaint, and when only superficial peritoneal implants or ovarian endometriomas < 5 cm are 33 
present, while progestogens should be preferred in women with severe deep dyspareunia and when 34 
infiltrating lesions are identified. 35 
 36 
KEYWORDS: endometriosis, dysmenorrhoea, dyspareunia, pelvic pain, oral contraceptives, 37 
progestogens, dienogest, GnRH agonists, GnRH antagonists 38 
39 
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1. INTRODUCTION: "GIMME SOME TRUTH"* 40 
*Lennon J. In: Imagine. U.K., Apple Records, 1971 41 
 42 
Numerous useful literature reviews on medical treatment for endometriosis have been published during 43 
recent years. Several of them are systematic and some include meta-analyses [1-4]. In most reviews, 44 
not only available drugs are evaluated, but also novel compounds under investigation [5-8]. Therefore, 45 
here we have tried to address the issue from another perspective, that is, defining the conceptual 46 
framework underpinning hormonal therapy for endometriosis; suggesting theoretical and practical 47 
instruments for selecting, interpreting, and implementing data on the medications most frequently used 48 
to treat endometriosis; and describing the general healthcare scenario in which physicians have to act 49 
together with their patients. In addition, the position of scientific institutions and authoritative experts 50 
in the field on specific controversial issues has been addressed. 51 
 Concerning the first point, the common final mechanism of action of hormonal drugs, and the 52 
reasonable expectations regarding their use should be highlighted once more. With few exceptions, 53 
different drugs, through diverse endocrine pathways, achieve a similar end-result, i.e., interference with 54 
pituitary gonadal stimulation, anovulation, induction of a steady hormonal milieu, and reduction or 55 
suppression of menstrual flow. If the ectopic endometrium derives from the mucosa lining the uterine 56 
cavity, the response to gonadal hormones’ variations may not be substantially different from that of the 57 
original epithelium, despite purported peculiar endocrine metabolism within extra-uterine implants 58 
(progesterone resistance; increased local oestrogen synthesis). Indeed, compounds have been developed 59 
to suppress the growth and the activity of the ectopic mucosa, precisely based on the principle that the 60 
ectopic endometrium responds to variations in circulating ovarian steroids similarly to the intrauterine 61 
one [9]. 62 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Vercellini et al., 4 
Nevertheless, the hypo- or atrophic glandular state induced by hormonal drugs is temporary by 63 
definition, as no definitive cytoreductive action can be expected by simply altering ovarian steroid 64 
levels. If adequately stimulated, the atrophic endometrium of a postmenopausal woman may resume its 65 
proliferative potential even after years of profound hypo-oestrogenism. Therefore, until hormonal 66 
compounds will be used in women with endometriosis, disease control is a sensible goal, whereas 67 
disease cure is not. Given their mechanism of action, current medications for endometriosis works 68 
during treatment, whereas there seems to exist no rationale to hypothesize an enduring effect after 69 
treatment discontinuation.    70 
However, some authoritative experts in the field of endometriosis have a different opinion and 71 
maintain "there is evidence to suggest that in many women who do not respond to therapy, symptoms 72 
return after cessation of treatment, even after short follow-up periods" and "there remains an unmet 73 
clinical need among women with endometriosis for a specific disease-modifying therapy to provide 74 
long-term symptom relief that persists after the treatment period" [4]. Women afflicted by 75 
endometriosis-related pain are eagerly waiting the advent of such intelligent drugs able to discriminate 76 
between the eutopic and the ectopic endometrium and to destroy selectively the latter one. In fact, only 77 
this type of drug would allow treatment for a limited period of time, achieving a long-lasting cure of 78 
pelvic endometriosis, but at the same time without causing uterine sterility due to disappearance of the 79 
intrauterine endometrium. How this differential effect could be obtained remains an unanswered 80 
question. In this regard, information from ongoing or completed trials on novel drugs for endometriosis 81 
is currently discouraging [9-11]. 82 
 Comparing endometriosis with another frequent chronic disorder outside the gynaecological 83 
field may help clarify the issue further. Authoritative gastroenterologists do not maintain that proton 84 
pump inhibitors (PPIs) are inadequate for the treatment of severe erosive gastroesophageal reflux 85 
disease (GERD) because not all patients respond satisfactorily to medical treatment, or some of them 86 
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report side effects, or almost all of them experience quick and severe symptom recurrence at drug 87 
discontinuation [12,13]. In fact, generally no medical therapy is effective on all patients with a chronic 88 
condition; effective drugs with no side effects just do not exist; and medications for chronic disorders 89 
are, by definition, symptomatic. Moreover, also in this case rapid symptom recurrence at drug 90 
discontinuation is expected and constitutes no surprise. Indeed, the development of PPIs has been 91 
beneficial for about two thirds of patients suffering from GERD whose symptoms were not sufficiently 92 
relieved by previously available therapies. The only reasonable alternative to PPIs is here a complex 93 
surgical procedure such as Nissen antireflux fundoplication, diaphragmatic hiatoplasty and fundopexy, 94 
with the well-known associated short- and long-term complications [14]. In fact, authoritative experts 95 
in the field recognize that PPIs, without surgery, must be taken for decades, precisely because they are 96 
not definitively curative. Therefore, "inefficacy", is here defined as lack of symptom relief during 97 
treatment and not after treatment [12,13].  98 
 Until agreement will be achieved on these two concepts, i.e., a similar response of ectopic and 99 
eutopic endometrium to hormonal compounds and the temporary pharmacological effect of currently 100 
available drugs, physicians and investigators will possibly nurture unfounded expectations. More 101 
importantly, when using medications for a few-month periods, patients might not receive a treatment 102 
that adequately limit the physical and psychological consequences of endometriosis. 103 
 Accepting the above principles means accepting that medical treatment for endometriosis may 104 
be needed for years. This also means that when medications are compared in randomised, controlled 105 
trials (RCTs), they should not be assessed only in terms of efficacy on pain. According to the Initiative 106 
on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), a multi-factorial 107 
evaluation is needed to determine whether a difference between the effect of an experimental drug and 108 
that of an available alternative option for the treatment of chronic pain is clinically meaningful [15]. In 109 
fact, in order to define a clinically meaningful between-group differences, several factors in addition to 110 
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pain improvement should be considered, including safety, tolerability, improvements in physical and 111 
emotional functioning, and cost. Thus, whether a difference in pain reduction is worth a change in the 112 
medications used for a given condition is not only a matter of effect size, but rather of a balanced 113 
assessment of the overall risk-benefit ratio. Consequently, to quantify the magnitude of change that is 114 
considered clinically meaningful to chronic pain patients, the authors recommend to use not only 115 
central tendency statistics (e.g., means ± SD or SEM), but rather anchor-based methods, such as patient 116 
ratings of patient satisfaction. According to the authors, “Although not without shortcomings, the use of 117 
global measures of improvement or overall treatment satisfaction in chronic pain trials allows patients 118 
to provide their integrated evaluation of a treatment, including but not limited to relief of pain, and 119 
such measures therefore have unique value as anchors in establishing clinical importance” [15]. 120 
In this regard, ideally our clinical goal is complete elimination of pain [16], provided this primary aim 121 
does not compromise safety, quality of life, and economic stability of women and their families. 122 
Otherwise, a reasonable compromise between all of these factors could be preferable, especially when 123 
prolonged periods of treatment are foreseen. For this reason, in the present review particular emphasis 124 
has been put on the overall “therapeutic balance” of various medications, as well as on patient 125 
satisfaction, an important global patient reported outcome, rather than on pain score variation as an 126 
isolated measure of the effect size of treatments.   127 
 128 
2. PROS AND CONS OF COMBINED ORAL CONTRACEPTIVES 129 
In a large, multicentre, placebo-controlled RCT conducted in women with symptomatic endometriosis, 130 
a low-dose OC substantially improved not only dysmenorrhoea, but also other pain symptoms, 131 
including non-menstrual pain and deep dyspareunia [17]. The findings of this Japanese study confirm 132 
the vast amount of published data concerning the appreciable degree of satisfaction with treatment that 133 
can be achieved with OCs in patients with the disease [3; Table 1]. However, Casper suggested that 134 
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progestogens should be preferred to OCs as a first-line treatment, based on the consideration that 135 
oestrogen and progesterone receptors would be, respectively, over- and under-expressed in ectopic 136 
endometrial implants [29]. Thus, administering OCs would be counterproductive, resulting in oestrogen 137 
dominance in the presence of progesterone resistance, with the potential risk of lesion progression. 138 
Interestingly, Casper notes that the amount of ethinyl-oestradiol (EE) contained even in so-called low-139 
dose OCs (20 to 30 µg EE) is supraphysiologic, as 5 µg of EE are equivalent to about 1 mg of 140 
micronized oestradiol or 0.625 mg of conjugated equine oestrogens [29].  141 
 According to Casper [29], this hypothesis is supported by clinical data suggesting that previous 142 
use of OCs is associated with an increased risk of endometriosis in general [30] and of deep lesions in 143 
particular [31]. On the other hand, it has also been demonstrated that dysmenorrhea as a reason to 144 
initiate OCs is significantly more common in women with a subsequent diagnosis of 145 
endometriosis than in women without the disease [31]. In other words, undiagnosed endometriosis 146 
likely was already present before OC use, and OCs were initiated precisely to relieve endometriosis-147 
related pain. Confounding might thus explain the previously reported mild association between 148 
endometriosis and past OC use [32]. The currently available epidemiological data do not support a 149 
pathogenic role of OCs in the development of endometriosis [30], and more robust evidence seems to 150 
be needed before depriving many patients of a safe, well tolerated, and affordable modality to relieve 151 
endometriosis-associated complaints. 152 
 Nevertheless, oestrogens do have a stimulatory effect on the metabolic activity of the 153 
endometrial mucosa, be it within or outside the uterine cavity. Therefore, when OCs are chosen as a 154 
modality to manage endometriosis, combinations with the lowest possible oestrogen dose should be 155 
chosen, such as those with only 15-20 µg of EE or 1.5 mg of 17 β-oestradiol (E2). Moreover, a very 156 
low oestrogen dose generally translates in a very limited amount of withdrawal bleeding secondary to 157 
minimal endometrial growth [33]. Indeed, menstrual flow is more abundant in women with 158 
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endometriosis than in those without the disease [34]. This may favour transtubal retrograde blood flow 159 
with increased likelihood of displacement of endometrial fragments in the pelvis and increased 160 
oxidative stress derived from saturation of the phagocytic capacity of pelvic macrophages toward 161 
refluxed erythrocytes [35]. Reducing monthly uterine blood flow by using very-low-dose OCs may 162 
translate in a substantial reduction also of retrograde flow and of the consequent pelvic oxidative stress 163 
that underpin the development of endometriosis, the inflammatory status, fibrosis generation, and pain 164 
insurgence [36]. Data from RCTs indicate that an OC containing 1.5 mg of 17 β-oestradiol and 2.5 mg 165 
of nomegestrol acetate (NOMAC) in a 24/4 formulation is associated with a prevalence of absent 166 
scheduled bleeding as high as 30% [37]. 167 
Finally, in addition to limiting endometriotic implant metabolism and minimizing monthly 168 
withdrawal bleeding, using OCs with a very low oestrogen content has the additional advantage of 169 
reducing the thrombotic risk. In fact, it has been repeatedly observed that the risk of both venous and 170 
arterial thrombosis is associated not only with the type of progestin included in OCs, but also with the 171 
oestrogen dose [38-41]. The use of decision aids may greatly help patients understand the actual 172 
increase in risk of thrombosis, as well as that of breast cancer, associated with prolonged OC use [42]. 173 
Detailed instructions for physicians on how to use the patient decision aid are freely available [43]. 174 
 Two questions may here spontaneously arise: if reducing the amount of uterine bleeding is 175 
deemed important, why not systematically using OCs continuously instead of cyclically? Moreover, if 176 
a stimulatory effect of even a very low oestrogen dose cannot be ruled out, why not using progestogens 177 
as a first-line treatment anyway? 178 
 Regarding cyclic versus continuous OC use, the writing Committee of the guideline NG73 179 
"Endometriosis: diagnosis and management", issued by the National Institute for Health and Care 180 
Excellence (NICE), stated "The evidence showed that cyclic use of the combined oral contraceptive pill 181 
is effective, but the Committee were also aware that continuous and tricycling (where three packets are 182 
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taken in a row, followed by a pill free interval) use of the pill are used in clinical practice, and 183 
although evidence was not available on these regimens in the literature, the Committee have found in 184 
their experience that these were also effective with limited adverse events" [44, page 236]. 185 
The advantage of continuous OC use is, as expected, a reduction of dysmenorrhoea compared 186 
with cyclic OC use. However, when pooling published data, no statistically significant differences were 187 
observed between the two treatment schedules in other pain symptoms, including deep dyspareunia, as 188 
well as in postoperative ovarian endometrioma recurrence rate [45]. 189 
 On the other hand, using OC continuously increases the likelihood of erratic bleeding that, if not 190 
promptly dealt with via tailored cycling [17], may cause prolonged pain [3]. Moreover, in the absence 191 
of clear and substantial benefits of continuous over cyclic OC use, priority should be given to 192 
individual patient preference. Some women may prefer the absence of monthly uterine blood flows, 193 
whereas others may feel reassured by them, considering amenorrhoea a non-physiological condition 194 
despite in-depth information. Thus, cyclic OC use may increase therapeutic compliance in the latter 195 
patients. 196 
 More in general, women with endometriosis are psychologically vulnerable and may suffer 197 
from disease labelling [46-48]. The psychological implications of any medical intervention should be 198 
carefully weighed, especially in adolescent and young patients. In these latter cases, not only using a 199 
drug that is associated with fertility and not considered a "therapeutic" for a specific illness, but also 200 
using it in the same manner as healthy friends, schoolmates, or colleagues do, may be reassuring, thus 201 
reducing the psychological consequences of feeling diseased. However, research is needed in this 202 
regard. If OCs do not need to be always used continuously from the very beginning, a shift from cyclic 203 
to continuous OC use may be suggested specifically in those women who experience pain at 204 
withdrawal bleeding. It has been demonstrated that four out of five patients with persistent 205 
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dysmenorrhoea despite cyclic OC use, are satisfied two years after a shift to continuous use of the same 206 
low-dose OC [49]. 207 
 Regarding the possible use of progestogens as first-line medical therapy in all women with 208 
endometriosis, in addition to the above psychological aspects, it should also be taken into account that 209 
treatments may be needed for years. Therefore, safety aspects are of utmost importance here. The 210 
progestogens most frequently studied in women with endometriosis are nor-ethisterone acetate 211 
(NETA), and dienogest (DNG) [29]. Indeed, both progestogens are associated with potential safety 212 
drawbacks, as the former may modify serum cholesterol lipoprotein distribution [21,50], whereas the 213 
latter may decrease bone mineral content [51-53]. Whether these variations in surrogate markers might 214 
translate into increased incidence of cardio-vascular events or pathologic fractures is currently 215 
unknown, also considering that this information would be available in the distant future, given the 216 
young age of women who have used or are using these progestogens. Most low-dose OCs do not alter 217 
serum lipid profile and do not decrease bone mineral content, and may be safely used for many years. 218 
 Moreover, as demonstrated by Harada et al. [17], the number of days of spotting are less and 219 
management of bleeding episodes is easier in women using an OC with tailored cycling (a 4-day tablet-220 
free interval after three consecutive days of bleeding and/or spotting), than in those using dienogest. 221 
This may impact on health-related quality of life (HRQL) and patient satisfaction. More in general, 222 
OCs are the medication associated with the lowest risk of discontinuation due to adverse events, 223 
compared with progestogens alone (oral or intramuscular) and GnRH agonists with or without add-224 
back therapy [44, page 203]. 225 
 In addition, OCs are contraceptive by definition, whereas progestogens (and GnRH agonists and 226 
antagonists) are not. Consequently, despite the recognised anti-gonadotropin activity of progestogens 227 
and the anovulatory state generally associated with currently indicated daily doses, women should be 228 
formally advised to use barrier contraception, with potential consequences on long-term treatment 229 
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adherence. Indeed, part of endometriosis patients would have used OCs for contraceptive purposes 230 
anyway, independently of their disease. Therefore, the opportunity cost of prescribing OCs in these 231 
circumstances is nil, as using OCs as a first-line treatment for endometriosis in these women would not 232 
displace health-care resources compared with a high-cost progestogen such as dienogest. 233 
 Finally, Casper correctly maintains that the use of OCs for endometriosis is "off-label". 234 
Nonetheless, in several international guidelines issued by authoritative societies and professional 235 
organisations, OCs are included among the first-line medications to be used in symptomatic women 236 
[44,54-57]. In particular, recommendation #37 of the recent guideline NG73 "Endometriosis: diagnosis 237 
and management" issued by the NICE states "Offer hormonal treatment (for example, the combined 238 
oral contraceptive pill or a progestogen) to women with suspected, confirmed or recurrent 239 
endometriosis" [44]. At the same time, the Committee notes that “At the time of publication (September 240 
2017), none of these medicines had UK marketing authorisations for this indication. The General 241 
Medical Council (GMC), in its Prescribing guidance: prescribing unlicensed medicines, states that 242 
although doctors should usually prescribe licensed medicines for their licensed indications, they may 243 
prescribe unlicensed medicines when it is necessary to do so to meet the specific needs of the patient. 244 
[…] It also states that when prescribing an unlicensed medicine is supported by authoritative clinical 245 
guidance (such as a NICE guideline), it may be sufficient to describe in general terms why the medicine 246 
is not licensed for the proposed use or patient population” [44, page 238].  247 
 248 
3. PROS AND CONS OF PROGESTOGENS 249 
Several progestogens have been evaluated for the treatment of endometriosis using different modalities 250 
of administration, including the oral, intramuscular, subcutaneous, and intrauterine route [see, as 251 
reviews, 3 and 58]. Some characteristics of the mostly studied progestogens are shown in Table 2. 252 
Low-cost progestogens include medroxyprogesterone acetate (MAP), nor-ethisterone acetate (NETA), 253 
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levonorgestrel (LNG), and nomegestrol acetate (NOMAC). Dienogest (DNG) is the only high-cost 254 
progestogen currently licensed for the treatment of endometriosis. 255 
 Medroxyprogesterone (MAP) acetate has been used by the oral, intramuscular, and 256 
subcutaneous route. Despite findings from RCTs demonstrated a similar effect on pain of subcutaneous 257 
depot MAP (DMPA) and an intramuscular GnRH agonist [66,67], this progestogen has not gained vast 258 
popularity for endometriosis treatment. Erratic bleeding may be burdensome to manage and the 259 
anovulatory state may extend well behind the predicted three-month DMPA injection duration [68]. 260 
This may be problematic in case of insurgence of untoward effects or pregnancy desire. The cost of 261 
intramuscular 150 mg DMPA is very low. Findings on the use of MPA by the oral route are scanty. 262 
Due to the lack of direct comparisons with other progestogens, it is unclear whether the currently 263 
limited use of MPA for endometriosis is due to suboptimal efficacy or tolerability or other reasons.  264 
 Oral NETA, at the dose of 2.5 to 5 mg per day, has been repeatedly assessed in observational 265 
studies and a RCT [21, 69-76]. In particular, NETA was demonstrated effective in patients with deep 266 
dyspareunia and rectovaginal lesions [73,74]. The reduction in pain at intercourse was gradual but 267 
progressive during time [73]. The residual androgenic activity of NETA causes part of the untoward 268 
effects experienced by women using this drug, such as weight gain, acne, and seborrhoea. On the other 269 
hand, being partly metabolised to oestradiol [50,77], NETA does not cause hypo-oestrogenic effects 270 
and may be used for prolonged period without detrimental consequences on bone mineral content. 271 
 Levonorgestrel has been used via an intrauterine device releasing very-low progestin doses 272 
during a 5-year period (LNG-IUD). Thus, despite the high cost of the device, the resulting yearly cost 273 
progressively decreases with duration of use. The effect of the LNG-IUD has been assessed in five 274 
RCTs. When evaluated as a postoperative measure, LNG-IUD use was associated with a significantly 275 
lower dysmenorrhoea recurrence rate and higher HRQL compared with expectant management. No or 276 
limited effect was observed on deep dyspareunia [20,78]. Moreover, the effect of the LNG-IUD on 277 
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pelvic pain symptoms and HRQL was similar to that of a GnRH agonist [79], though patient 278 
satisfaction was lower [80].  279 
Advantages of the LNG-IUD include avoidance of daily drug intake and contraception. 280 
However, ovulation is not inhibited, except for the first few months after insertion. This constitutes an 281 
important disadvantage, because it has been demonstrated that ovarian endometriomas originates from 282 
haemorrhagic corpora lutea [81], and that the post-operative endometrioma recurrence rate is about 283 
10% per year for the first quinquennium of follow-up if ovulation is not suppressed [82,83]. The effect 284 
of the LNG-IUD in the prevention of postoperative endometrioma recurrence has been investigated in a 285 
RCT comparing two groups of 40 participants each allocated to receive the device or not after 286 
laparoscopic excision of endometriotic cysts [84]. The endometrioma recurrence rate did not differ 287 
significantly at 30 month-follow-up, being 25% in the LNG-IUD group and 37% in the control group. 288 
The authors concluded that long-term maintenance therapy using a LNG-IUD is not effective for 289 
preventing endometrioma recurrence. Therefore, the best candidate for the use of the LNG-IUD seems 290 
to be a parous woman with no further pregnancy desire and with dysmenorrhoea as her main or only 291 
pain symptom. The LNG-IUD may not have the same effect of other progestogens used systemically 292 
on deep dyspareunia. 293 
Nomegestrol acetate is a progestogen used for the treatment of irregular uterine bleeding and 294 
dysmenorrhoea that has been tested in an animal model of endometriosis with favourable preliminary 295 
results [85]. Nomegestrol acetate has pharmacological and hormonal properties similar to dienogest 296 
[Table 2] and, when combined with oestradiol in an OC used cyclically (NOMAC, 2.5 mg; oestradiol, 297 
1 mg], was frequently associated with absence of withdrawal bleeding [37]. This progestogen is 298 
inexpensive and well tolerated, but further studies are needed in women with symptomatic 299 
endometriosis. 300 
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Oral dienogest, at the daily dose of 2 mg, is the progestogen supported by the largest evidence 301 
originated from RCTs and cohort studies [86]. Dienogest was better than placebo and not inferior to a 302 
GnRH agonist in relieving endometriosis-associated pain [52,87-89]. Compared with NETA in a before 303 
and after study, it was similarly effective on pain, but better tolerated [75]. Despite this, its 304 
effectiveness was inferior to that of NETA because, due to the high drug cost, about one third of 305 
women declined its use.  306 
Indeed, cost seems to be the only major drawback of this effective and well-tolerated 307 
progestogen, and the price appears difficult to justify, also considering that DNG is an old molecule 308 
synthesized in 1979 and investigated in the 80’ by Jenapharm as a potential component of an OC. In 309 
Italy, the yearly cost of treatment with dienogest for endometriosis, 2 mg/day per os, is €730. In the 310 
same country, some monophasic OCs combining 30 µg of EE and 2 mg of dienogest per pill are 311 
marketed with the classic 21/7 schedule at the cost of €14-15 per pack. This means that the identical 312 
amount of dienogest (2 mg) is sold at a prize of about €0.7 when combined with EE and used for 313 
contraception, and of €2 when marketed as monotherapy for the treatment of endometriosis. This 314 
policy ultimately affects specifically women suffering from endometriosis. 315 
 Overall, progestogens are safe, can be used when OCs are not tolerated or contraindicated [27], 316 
and should be preferred in women with deep lesions, including colorectal nodules, or those with deep 317 
dyspareunia as their main complaint [3,74,90,91]. Abundant evidence originated from controlled 318 
studies consistently demonstrates that about two thirds of patients are satisfied with the use of 319 
progestogens for symptomatic endometriosis [Table 3]. Side effects associated with these 320 
 drugs are frequent but seldom cause therapy abandonment. The main issue remains erratic bleeding 321 
that usually causes temporary pelvic pain relapse. In case of persistent bleeding, discontinuing 322 
treatment for some days was found effective in restoring amenorrhoea [20-22,75]. Comparative 323 
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effectiveness research is still needed in order to identify those molecules and/or those doses associated 324 
with the smallest risk of spotting and breakthrough bleeding.  325 
 326 
4. CHOOSING GnRH AGONISTS AND ANTAGONISTS WISELY 327 
Several studies were conducted in the past decades on the effect of GnRH agonists for the treatment of 328 
endometriosis. The profound hypo-oestrogenic state achieved during the use of these drugs explains 329 
their efficacy in terms of pelvic pain relief and, at the same time, their limited tolerability and safety. 330 
The combination of GnRH agonists with add-back therapy (generally a bone-sparing progestogen such 331 
as NETA or an oestrogen-progestogen hormone replacement therapy) limits vasomotor side effects and 332 
prevent bone resorption, but further increases costs.  333 
 In a RCT, the combination of leuprolide in a 12-week depot formulation plus NETA 5 mg/day 334 
as add-back therapy was not superior to an OC containing NETA 1 mg and EE 35 µg in reducing pain 335 
symptoms and improving psychological status and sexual function [96]. The cost of the 48-week 336 
treatment was $8,006 with leuprolide depot 11.25 mg plus NETA and $454 with the OC. According to 337 
the authors, to achieve a reduction in pain that was not significantly different from OC therapy, a 48-338 
week treatment with leuprolide would cause an extra-cost of $7,552 per patient. 339 
 The results of two large phase 3 trials on the effect of elagolix, a non-peptide GnRH antagonist, 340 
for the treatment of endometriosis were recently published [97]. The GnRH antagonist at the oral daily 341 
dose of 150 or 400 mg was tested against a placebo.  At 3-month evaluation the percentages of women 342 
who had a clinical response with respect to dysmenorrhoea were 43-46% and 72-76% in, respectively, 343 
the lower- and the higher-dose elagolix group, compared with 20-23% in the placebo group. This is 344 
expected, given that the frequency of dysmenorrhoea is inversely related to the frequency of 345 
amenorrhoea achieved by any hormonal drug. In fact, at the end of the 6-month study period, the 346 
percentage of participants experiencing amenorrhoea in the higher elagolix dose group in the two trials 347 
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varied from 47 to 66%. The differences with respect to non-menstrual pelvic pain were smaller, as the 348 
percentages of women who had a clinical response were 50% and 55-58% in, respectively, the lower- 349 
and the higher-dose elagolix group, compared with 37% in the placebo group.  350 
The tolerability and safety profile of elagolix reflected the induced hypo-oestrogenic state. Hot 351 
flushes were the most frequent side effect, reported by 42-48% of women in the higher elagolix dose 352 
group. The mean percent bone mineral density (BMD) reduction at the lumbar spine observed at 6-353 
month follow-up in women in the higher elagolix dose group varied from -2.49 to -2.61. A reduction of 354 
more than 5% in BMD at the lumbar spine was identified in 16-21% of women in that group. Elagolix 355 
did not completely suppress ovulation at either of the doses. Women were instructed to use two forms 356 
of non-hormonal contraception (e.g., condom plus spermicide) but, despite this, eight women using 357 
elagolix conceived. In one of the two trials, the unplanned pregnancy rate in women using elagolix was 358 
over 1% (6/497). 359 
Elagolix has been assessed versus an active comparator in a single, phase 2 multicentre RCT 360 
[68]. A daily elagolix dose of 150 mg was not inferior to a depot three-monthly subcutaneous MPA 361 
formulation in terms of BMD variation and pain symptom reduction. It is interesting to note that the 362 
effect of cheap DMPA was similar to that of the novel experimental drug. Three out of 168 participants 363 
(1.8%) allocated to elagolix got pregnant compared with none in the DMPA group. 364 
Elagolix induces a dose-dependent suppression of ovarian oestradiol production. Indeed, the 365 
induction of a hypo-oestrogenic milieu is a mainstay of hormonal treatment of endometriosis. The 366 
possibility of modulating the degree of induced hypo-oestrogenism has on one hand the advantage of 367 
limiting subjective and metabolic side effect, but on the other hand exposes to the risk of unplanned 368 
conception as ovulation is inconsistently inhibited. The teratogenic potential of GnRH antagonists is 369 
currently undefined, and it is unclear if women will have to perform serial urine tests during treatment 370 
in order to discriminate between drug- and pregnancy-induced amenorrhoea. The need for barrier 371 
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contraception may limit compliance and potentially increase the discontinuation rate. In addition, a 372 
clear dose-response effect on pain has been observed. This means that the degree of pain relief and the 373 
incidence and severity of untoward effects are positively correlated. In case higher elagolix doses have 374 
to be used to control severe pain symptoms, whether add-back therapies should be added to allow 375 
prolonged drug needs to be ascertained. Moreover, whether oral daily use is preferable to monthly or 376 
three-monthly intramuscular or subcutaneous depot injections is a subjective matter, and different 377 
patients may prefer either one or the other modality. GnRH antagonists avoid the flare-up phase, 378 
typical of GnRH agonists. However, injecting depot GnRH agonists during the mid-luteal phase 379 
prevents this potential drawback. Alternatively, using an oral progestogen for the first 7-10 days after 380 
the first GnRH agonist injection may avoid the initial gonadotropin surge. 381 
Therefore, unless GnRH antagonists will be marketed at lower price than GnRH agonists, the 382 
advantages of the former compounds over the latter ones may reveal smaller than expected. Finally, 383 
further trials should be conducted in order to define the incremental benefit of GnRH agonists and 384 
antagonists, in terms of pain relief and patient satisfaction, over low-dose OCs or low-cost oral 385 
progestogens. The opportunity cost associated with the use of these molecules should also be evaluated. 386 
GnRH agonist may be used for a few months before starting progestogens [98,99], or intermittently 387 
during progestogen treatment in case of phases of pain relapse or prolonged bleeding and, combined 388 
with add-back therapy, in patients not responding to progestogens and unwilling to undergo surgery or 389 
in those at very high surgical risk.  390 
 391 
5. SELECTIVE PROGESTERONE RECEPTOR MODULATORS FOR ENDOMETRIOSIS: A SAFE 392 
OPTION? 393 
Selective progesterone receptor modulators (SPRMs) interact with progesterone receptors and 394 
should inhibit endometrial cell proliferation, and suppress uterine bleeding and synthesis of 395 
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prostaglandin [100]. In most reviews on medical treatment of endometriosis these drugs are included 396 
among the promising future compounds under investigation [6,8,101].  However, the evidence in 397 
support of SPRM for endometriosis appear limited. Kettel et al. [102] treated nine patients with 398 
mifepristone, 50 mg/day per os for six months and reported pain symptom relief in all of them without 399 
hypo-oestrogenic side effects. In one patient liver enzymes increased during treatment. The same drug 400 
at a lower dose (5 mg/day) improved pain in six out of the seven women studied, but caused irregular 401 
bleeding in four of them [103]. 402 
The effect of asoprisnil was assessed in a double-blind, placebo-controlled, RCT conducted on 403 
130 participants [104]. The three doses studied (5, 10, 25 mg/day for 12 weeks) all reduced pain 404 
symptoms scores significantly and induced amenorrhoea in a dose dependent manner, with no effect on 405 
serum oestradiol levels [104]. However, the full report of this industry-sponsored trial does not seem to 406 
have been published in a peer-reviewed journal. Chwalisz et al. maintained that asoprisnil may provide 407 
a novel, tissue-selective approach to control endometriosis-related pain [101]. However, according to 408 
Tosti et al. [100] and Bedaiwy et al. [6], the trials on asoprisnil were stopped because of development 409 
of endometrial hyperplasia in some women. In our view, this is precisely the reason to be careful when 410 
hypothesizing the use of SPRM in women with endometriosis.  411 
Most data regarding the long-debated endometrial effects of SPRM originates from the use of 412 
these drugs in women with uterine fibroids. According to some pathologists, the so called PAEC 413 
(progesterone receptor modulators associated endometrial changes) should not be considered as true 414 
cytological or structural atypia [105]. Despite this, the intermittent treatment modality indicated for 415 
ulipristal acetate (three months on/two months off) appears dictated specifically to prevent the 416 
endometrial effects of this class of drugs. In fact, SPRMs show anti-progestogenic activity that might 417 
lead to endometrial hyperplasia after prolonged, uninterrupted use. Thus, "intermittent courses allow 418 
menstrual shedding of the endometrium and allow a complete menstrual cycle to take place between 419 
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each treatment course, with physiological progesterone influence on the endometrium" [106; page 46]. 420 
In light of available histological evidence, Stewart highlights that "long-term safety data are lacking to 421 
show that progesterone modulators do not increase the risk of endometrial abnormalities" [107]. 422 
 Hyperplasia of eutopic endometrium usually can be easily identified at transvaginal 423 
ultrasonography and, in this case, an aspiration biopsy can be readily obtained. The problem here is that 424 
hyperplastic modifications of endometrium at ectopic sites could go undetected. In addition, 425 
hyperplasia of intrauterine endometrium may not translate inevitably into increased mortality from 426 
endometrial adenocarcinoma, whereas the consequences may reveal dramatic in case atypical changes 427 
of ectopically implanted endometrium increase the incidence of “ovarian” endometrioid carcinomas. 428 
Indeed, it is currently accepted that most endometrioid and clear-cell ovarian adenocarcinomas 429 
originate from pelvic endometriosis [108]. Using a class of drug that may potentially induce 430 
endometrial hyperplasia precisely in women who are already at increased risk of developing 431 
endometrioid ovarian cancer [109] may raise safety concerns. 432 
Although on theoretical grounds SPRMs may constitute another medical option for women with 433 
endometriosis, more data are needed concerning the long-term effect on the endometrium and overall 434 
drug safety before they can be suggested for prolonged use.  435 
 436 
6. POSTOPERATIVE MEDICAL TREATMENT: ETHICS BEYOND EFFECTIVENESS 437 
It has been repeatedly demonstrated that lesion and symptom recurrence after surgery is substantially 438 
higher in women who undergo postoperative expectant management compared with those who use 439 
postoperative medical treatment [83,110]. The recurrence rate in the former group of women is around 440 
10% a year for the first five years of follow-up [82]. Data for longer periods of follow-up are limited. 441 
Endometrioma recurrence is detrimental for future fertility, and cyst excision is associated with reduced 442 
ovarian reserve [111,112]. The likelihood of conception after second-line surgery for recurrent ovarian 443 
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endometriomas is halved in comparison with that after first-line procedures for primary lesions [113]. 444 
Although this finding should be interpreted with caution because of obvious selection bias and possible 445 
confounding, measures aimed at reducing the risk of development of recurrent cysts after 446 
endometrioma excision seem of utmost importance in order to preserve the already compromised 447 
reproductive potential.  448 
 It has been observed that ovarian endometriomas developed from haemorrhagic corpora lutea 449 
[81]. Moreover, suppressing ovulation by using OCs dramatically reduced the postoperative 450 
endometrioma recurrence rate [114]. This finding has been consistently and repeatedly confirmed by 451 
independent groups using different study designs [45,115,116]. The effect size appears unusually large, 452 
as the reduction in risk is over 80%. In a systematic literature review and meta-analysis, a recurrent 453 
endometrioma was identified in 8% of "always" OC users and in 34% women who underwent 454 
expectant management (pooled odds ratio 0.12; 95% C.I., 0.05 to 0.29). The effect of OC is strictly 455 
related to duration of use, as the risk increases soon after drug discontinuation. In fact, when "always" 456 
users were compared with "ever" users, and "ever" with "never" users, the pooled odds ratio was, 457 
respectively, 0.21 (95% confidence interval 0.11-0.40) and 0.39 (95% confidence interval 0.23-0.66), 458 
thus supporting the validity of the overall result [115]. The modality of OC use (i.e., cyclic vs 459 
continuous) does not seem to influence the outcome [45,115]. 460 
In the recent guideline NG73, the NICE Committee maintained “in view of the high rate of 461 
recurrence of endometriosis, affecting long-term quality of life for many women, improvement in long-462 
term control of the condition was felt by the Committee to be clinically very important. The Committee 463 
were aware of the high rate of reoperation for endometriosis with associated risks of surgery and, as 464 
there was strong evidence to support this, considered that avoidance of repeat surgery by the use of 465 
long -term medical therapy would be beneficial. […] Based on the evidence, the beneficial effect of all 466 
hormonal therapies was similar (probably because all work through similar mechanisms) and so the 467 
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Committee considered the adverse effects of the various treatments in making their recommendation, as 468 
there are known side effects with hormonal treatments that some women may wish to avoid. In general, 469 
the Committee considered that the combined oral contraceptive pill or long-acting reversible 470 
progestogen contraceptives were the most acceptable treatments” [44, page 303]. Accordingly, 471 
recommendation #46 of NICE guideline NG73 states “After laparoscopic excision or ablation of 472 
endometriosis, consider hormonal treatment (with, for example, the combined oral contraceptive pill), 473 
to prolong the benefits of surgery and manage symptoms” [44]. 474 
Given the abundant evidence on the beneficial effects of OCs and progestogens after surgery for 475 
endometriosis, and considering the unequivocal recommendations issued by authoritative 476 
organizations, not informing patients and not adequately explaining the advantages of prolonged 477 
postoperative hormonal treatment, and not suggesting it in women not seeking pregnancy immediately, 478 
may nowadays raise ethical perplexities. Clinical behaviours that deprive women of demonstrated, 479 
large benefits and that expose them to the risk of repeated surgical procedures and further reduction of 480 
the reproductive potential should be discouraged. The final decision is left to the patient. 481 
 482 
7. A LESION-BASED, THREE-TIERED RISK STRATIFICATION SYSTEM 483 
Variability in the response to medical treatments is observed among patients with symptomatic 484 
endometriosis. This may be due to several factors, including the different number of nerve fibres close 485 
to or within endometriotic lesions, various degrees of peripheral as well as central sensitisation (type 486 
and degree of excitatory neural response to stimuli and endogenous pain-modulatory processes), 487 
symptom characteristics (e.g., dysmenorrhoea vs deep dyspareunia), and psycho-social factors [3,46-488 
48,117-119]. However, when trying to assess the phenotypic characteristics that are most predictive of 489 
individual variation in medical therapy outcomes, we suggest to give adequate weight to the type of 490 
lesion present [3]. We have proposed a differentiated approach based on what is known about the 491 
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natural course of different forms, as well as on the associated risk of clinical, anatomical, and surgical 492 
complications. 493 
a. Low-risk lesions  494 
According to the three-tiered risk stratification system [3], superficial peritoneal implants are 495 
considered “low-risk” lesions. In fact, based on the findings of several RCTs, superficial peritoneal 496 
lesions evaluated at follow-up laparoscopy progressed in only one third of women allocated to placebo 497 
or no treatment, and remained stable or regressed in the remaining two thirds [120,121]. Thus, the 498 
natural history of early peritoneal lesions appears highly variable. Although these limited lesions can be 499 
removed easily at laparoscopy and with a very low risk of surgical complication, they also usually 500 
respond well to OCs [3], which create a predominantly progestogenic milieu and may reduce or abolish 501 
retrograde menstruation [36]. The former action exerts an anti-inflammatory effect by inhibiting 502 
endometrial cell metabolism and favouring apoptosis [122,123]. In addition, early peritoneal implants 503 
alone are mostly found in young women [124] who, as previously considered, may be better candidates 504 
for treatment with OCs rather than with progestogen monotherapies. 505 
b. Medium-risk lesions 506 
Ovarian endometriomas may be categorised as “medium-risk” lesions for several reasons, 507 
including the demonstrated fertility implications. Their excision is generally not particularly difficult 508 
and the risk of immediate surgical complications is low. However, a local gonadal damage may result, 509 
with potential worsening instead of improvement of the likelihood of conception. The therapeutic goal 510 
in women not seeking pregnancy is achieving anovulation, as it has been demonstrated that ovulation is 511 
the main pathogenic mechanism for the development or progression of endometriomas [81]. Thus, low-512 
dose OCs, used cyclically or continuously, may be indicated in symptomatic women with typical 513 
unilocular endometriomas not wanting children, either as an alternative to first-line surgery or to avoid 514 
second-line procedures for cyst recurrence. There is no consensus on the maximum cyst diameter 515 
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above which surgery is deemed mandatory. Unfortunately, most guidelines on endometriosis are 516 
inconsistent or somewhat vague, as a cut-off of 3 cm, 4 cm, or no cut-off have all been indicated [55, 517 
56,125,126].  518 
According to the recent ACOG Practice Bullettin #174 on Evaluation and Management of 519 
Adnexal Masses [126], “Although endometriomas of 5 cm or more have been associated with lower 520 
ovarian follicle density, several studies have found similar fertility outcomes among women with or 521 
without endometriomas who underwent assisted reproduction. Thus, asymptomatic endometriomas do 522 
not require intervention for infertility”. Moreover, according to the First International Consensus 523 
Report on Adnexal Masses [127], unilocular endometriomas should be categorized among the “almost 524 
certainly benign” lesions. Endometriomas that have a “classic appearance” can benefit from 525 
conservative management, often with serial follow-up sonography. The members of the panel stated 526 
“endometriomas have a low association with malignancy, typically less than 0.8%. Therefore, […] it is 527 
prudent to follow these [cysts] over time to assess for morphologic changes, in particular, looking for 528 
lesions that show rapid growth or develop solid vascular elements. There is an increased risk of 529 
malignant transformation in larger endometriomas (>9 cm) and older women (>45 years). Overall, 530 
there is no definitive data to indicate that early surgical treatment of endometriotic implants is 531 
associated with a reduced risk of malignancy”. 532 
The above authoritative positions appear aligned with the proposal of Muzii et al. to initially 533 
withhold surgery and verify whether OCs relieve pain in women with endometriomas smaller than 5 534 
cm, and to schedule “serial ultrasound scans, preferably after 3 to 6months if the cyst is diagnosed for 535 
the first time, and then yearly if there is no fast growth or change in sonographic features in the short-536 
term period” [45]. 537 
c. High-risk lesions 538 
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Deep fibrotic nodules and plaques infiltrating the rectosigmoid, vagina, parametria, and bladder 539 
constitute the really severe disease in terms of frequency and degree of pain symptoms, technical 540 
difficulties at excision, and risk of intra- and post-operative complications. In case of lesion 541 
progression, ureteral stenosis may also ensue. Progestogens, instead of OCs, should generally be 542 
considered the first-line medical treatment for these “high-risk” lesions. In fact, given the severity of 543 
the condition, it seems wise to avoid even a limited oestrogenic stimulus despite the potential 544 
drawbacks in terms of serum lipid pattern or bone mineral density variation. Progesterone receptors 545 
have been identified in all the above lesion types [128] and the findings of several studies consistently 546 
confirmed that about two-thirds of patients with deep endometriosis respond favourably to progestogen 547 
treatment [3,90,91]. In addition, OCs usually control well pain at menstruation, but less so pain at 548 
intercourse [129]. Progestogens have been demonstrated effective in improving deep dyspareunia 549 
associated with deep lesions of the posterior compartment [71,73,74,130,131]. Moreover, the 550 
intravaginal use of progestogens should be investigated in patients with the “deep lesion-deep 551 
dyspareunia” anatomic-clinical phenotype [132-134]. 552 
 553 
8. A SYMPTOM BASED, STEPPED-CARE APPROACH   554 
According to the guidelines on endometriosis management issued by major international scientific 555 
societies, different medications have substantially similar effects in terms of pain relief, but have 556 
different safety and tolerability profiles and sometimes very different costs. Consequently, safe, well-557 
tolerated, and inexpensive OCs and progestogens are suggested as first-line treatments in symptomatic 558 
patients [44,54-57]. Based on a systematic critical appraisal of the evidence, the NICE Committee 559 
confirmed two fundamental principles: 1) "all treatments led to a clinically significant reduction in 560 
pain on the VAS when compared to placebo. The magnitude of this treatment effect was similar for all 561 
treatments, suggesting that there was little difference between them in their capacity to reduce pain. No 562 
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other significant differences were found between the hormonal treatments" [44, page 198]; and 2) "it is 563 
known that there are a cluster of extremely cheap hormonal treatments (including the combined oral 564 
contraceptive pill) and a cluster of extremely high-cost treatments including dienogest and GnRHas" 565 
[44, page 230]. 566 
Any long-term therapeutic strategy for women with endometriosis-associated pain should be 567 
based on these two concepts. However, about one third of patients will not respond to OCs or 568 
progestogens owing to the subjective variability to drugs’ effect. Regrettably, the reliable identification 569 
before starting treatment of which women will respond successfully to which drugs, appears currently 570 
problematic. In this condition, it seems reasonable, practical, and cost-effective to use the safest, better 571 
tolerated, and inexpensive medications first, stepping up to less safe or less tolerated or more costly 572 
drugs only in case the former ones are ineffective, not tolerated or contraindicated [3, 91]. This 573 
stepped-care approach is indicated in women who are not seeking pregnancy, who prefer medical 574 
rather than surgical treatment, and who do not have absolute surgical indications, such as sub-occlusive 575 
bowel stenosis, obstructive uropathy, endometriomas over 5 cm in diameter, and adnexal masses of 576 
doubtful ultrasonographic characteristics.  577 
 According to this model, low-dose OCs should be used cyclically in women with peritoneal and 578 
ovarian endometriosis, stepping up to continuous use with tailored cycling only in those women with 579 
persistent dysmenorrhoea despite cyclic OC use. In case of inefficacy on pain during OC use, patients 580 
should step up to a low-cost progestogen such as NETA. Independently of pain relief, women should 581 
step up to progestogens also in case of intolerance to OC (e.g., migraine). Starting directly with a low-582 
cost progestogen should be considered in patients with deep lesions or with deep dyspareunia as their 583 
main complaint, as well as in those with contraindications to OCs. Stepping up from a low-cost to a 584 
high-cost progestogen (i.e., DNG) should be advised only in case of intolerance to NETA, as it has 585 
been demonstrated the DNG, being devoid of androgenic activity, is better tolerated than NETA [75]. 586 
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Shifting from NETA to DNG for inefficacy on pain is not supported by sufficient evidence. In case of 587 
inefficacy of or intolerance to progestogens, patients may step up to GnRH agonists or antagonists, 588 
provided they are thoroughly informed on the aims, pros and cons of this option. Informed patients 589 
should be invited to consider also the surgical alternative. This is particularly true the more a woman 590 
advances through the stepwise algorithm, as careful evaluation of potential benefits, potential harms, 591 
and costs of medical and surgical options may tip the balance in favour of the latter choice, especially 592 
when the procedure is presumably at low risk. 593 
According to Taylor, “the goal of endometriosis therapy should always be absence of pain; if 594 
this end point is not achieved with oral contraceptives, the patient should be offered more definitive 595 
therapy. Many patients fail to adequately respond to oral contraceptives while others develop progestin 596 
resistance with disease progression despite using a progestin based therapy […] The realization that 597 
all therapies have different efficacy and the availability of new endometriosis drugs will allow more 598 
rapid progression to definitive therapy” [16]. In this regard, the adoption of the above stepwise 599 
approach allows the identification of that third of patients that would benefit from the use of drugs 600 
associated with suboptimal safety or tolerability profiles or high costs. In fact, demonstration of the 601 
efficacy of dienogest and GnRH agonists and antagonists in exploratory RCTs should not translate in 602 
systematic prescription of these drugs to all women with symptomatic endometriosis in routine 603 
practice. This is particularly important considering that novel medications are generally more costly 604 
than existing ones and that obtaining reasonably priced treatments for our patients is difficult. Until 605 
robust data will demonstrate that new and costly drugs are curative and not just symptomatic, and 606 
therefore can modify the natural history of endometriosis, the stepped-care approach may prevent the 607 
needless prescription of those medications to at least two thirds of patients who do not need them.  608 
 609 
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9. TAYLORING MEDICAL THERAPY TO PROVIDE MINIMALLY DISRUPTIVE 610 
ENDOMETRIOSIS MANAGEMENT 611 
 Women with severely symptomatic endometriosis, in addition to pain, usually experience major 612 
worsening in health-related quality of life, psychological status, sexual functioning and marital 613 
relationship, social life, and school or work productivity [46-48,135-138]. This is the “burden of 614 
illness”. The International Minimally Disruptive Medicine Workgroup considers that patients with 615 
chronic disorders also experience the so-called “burden of treatment” [139] that, in the case of 616 
endometriosis, includes taking medications, managing side effects, attending gynaecological visits, 617 
performing imaging investigations and repeated blood tests, undergoing surgical procedures, self-618 
monitoring, lifestyle changes, administrative task to access and coordinate care, full or partial payment 619 
of treatments, and other hidden costs. 620 
The combined effect of the burden of illness and the burden of treatment may result disruptive 621 
for the life of women with endometriosis and their families. Awareness of the additive impact of these 622 
two factors on individual capacity to cope with the disease seems limited in the endometriosis scientific 623 
community. Indeed, taking into account the burden of treatment when selecting the type of medications 624 
to be used, may improve outcomes [139]. Planning long periods of medical therapy with OCs or 625 
progestogens has the potential to decrease greatly not only the burden of illness, but also the burden of 626 
treatment. Allowing women with endometriosis to live a life as normal as possible appears an 627 
important comprehensive goal. Substantially limiting lesion and symptom relapse for years, may 628 
greatly reduce the frequency of visits, tests, and procedures, as well as the economic impact of care. 629 
This may also aid in improving the degree of anxiety and depression of women, preventing in part the 630 
consequences of disease labelling [140]. This is precisely what can be obtained in about two thirds of 631 
patients with low-dose OCs and low-cost progestogens [3,9]. According to the International Minimally 632 
Disruptive Medicine Workgroup, “the value of care for patients should reflect the health outcomes 633 
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achieved and the degree of burden that patients and their caregivers must bear to achieve those 634 
outcomes” [139]. 635 
A minimally disruptive approach also seems aligned with the position of the Practice 636 
Committee of the American Society for Reproductive Medicine that indicates “endometriosis should be 637 
viewed as a chronic disease that requires a life-long management plan with the goal of maximizing the 638 
use of medical treatment and avoiding repeated surgical procedures” [56]. The same position is held in 639 
the NICE guideline NG73, when it states "the Committee agreed with the evidence and further 640 
highlighted that the benefit from hormonal treatments was due to their efficacy in stopping or reducing 641 
periods. There was a desire from the Committee to reduce the number of repeated operations for 642 
women with endometriosis, further supporting maintenance of pain relief using hormonal treatments 643 
wherever possible". [44, page 236] 644 
However, LeFevre warns that “every dollar spent on health care is someone’s income stream. 645 
In any move to do less, there will be efforts from those who lose income to push back” [141].   646 
 647 
10. PROSPECTUS: MEASURING CLINICAL EFFECTIVENESS, COST-EFFECTIVENESS, AND 648 
OPPORTUNITY COST 649 
Also in the endometriosis field, the technology tsunami is paving the way for costly interventions with 650 
still uncertain benefits and potential harms. Blood tests could greatly expand the boundaries of 651 
endometriosis diagnosis, blurring the limits between diseased and non-diseased populations. Genetic 652 
testing could be offered directly to consumers, transforming a potentially useful tool for assessing risk 653 
(and not for definite diagnosis) into an uncontrolled mean for home-made and misled screening of 654 
asymptomatic women. Robotic surgery is gradually replacing traditional laparoscopy despite the 655 
repeatedly demonstrated disadvantages in terms of costs and overall operating room time. In the same 656 
vein, new and presumably costly drugs are on the horizon. It is currently unclear to what extent, beyond 657 
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widespread enthusiasm, their entry into the market will modify the natural history of endometriosis and 658 
health-related quality of life of patients.  659 
 There is a dearth of comparative effectiveness research also in the field of medical treatment for 660 
endometriosis. Pragmatic trials conducted by independent investigators, and including a low-dose OC 661 
or a low-cost progestogen as a comparator, are needed to assess the actual incremental benefit of new 662 
drugs over currently used ones. Only the determination of that incremental benefit (if any) will allow us 663 
to understand if using novel medications is worth the extra cost. According to Dworkin et al., “The cost 664 
of a treatment is another important source of patient non-adherence with treatment, of course, and is 665 
also important in considerations of cost-effectiveness” [15].  666 
Patients may not benefit directly from explanatory trials, conducted for registration purposes, 667 
that include a placebo as a comparator, because defining the size of the effect over a placebo does not 668 
answer a meaningful question that matters to them. The same is partly true when GnRH agonists are 669 
used as comparators, because most patients do not use these drugs as their standard treatment. In this 670 
regard, we challenge the popular tenet suggesting that surgical devices are often introduced into 671 
practice without adequate comparative experimentation, whereas new drugs are subject to rigorous 672 
testing before entering the market. In the endometriosis field this may not be always true, as formally 673 
faultless methodology and clinical meaningfulness are not necessarily synonymous.  674 
The thresholds for cost-effectiveness that should be accepted when considering the opportunity 675 
cost of using dienogest and GnRH agonists and antagonists extensively in women with severe pain 676 
symptoms, are currently scarcely or not yet defined. The combination of high thresholds combined with 677 
high frequency of the condition implies that costly medications for symptomatic endometriosis would 678 
have a substantial impact on health care system budgets and, therefore, a large opportunity cost. 679 
Evaluation of opportunity cost should be included in analyses of economic evaluation of cost of 680 
implementation of every novel medical intervention for patients with endometriosis, be it for screening, 681 
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diagnosis, medical therapy, or surgical treatment. When novel drugs show a demonstrated large 682 
incremental benefit, in terms of pain relief and health-related quality of life, compared to OCs and 683 
progestogens, the use of additional resources and the associated opportunity cost may be justified. 684 
However, from a justice perspective, the magnitude of the effect, as well as the evidence on which the 685 
magnitude has been determined, should be carefully scrutinized [142,143]. If later studies conducted by 686 
independent groups will demonstrate lower than expected cost-effectiveness for novel drugs for 687 
endometriosis, then the a-priory accepted threshold might be exceeded with waste of money [144] and 688 
implications regarding the ethical principle of equitable distribution of finite health-care resources, as 689 
other patients (in and outside the endometriosis field) are potentially deprived of beneficial medical 690 
interventions (or care at large), although their needs might be similarly or even more pressing [145, 691 
146].  692 
  We may not be expert of health-care economic analysis. Still, we have the moral duty of 693 
reasoning on individual patient conditions in order to try to achieve the best possible outcome for that 694 
woman, at the same time avoiding the needless displacement of excessive resources, thus respecting the 695 
entire population of similar patients. It is a fact that low-dose OCs and low-cost progestogens allow 696 
adequate control of endometriosis symptoms and lesions in about two thirds of patients, including those 697 
with deep infiltrating forms. One third of women will need second-line medical therapies or surgery, 698 
and future genetic and pharmacological research should focus specifically on this population subgroup 699 
at worse prognosis with the objective of improving outcomes that matter to these patients.  700 
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SUMMARY 702 
Available medical treatments for symptomatic endometriosis act by modifying the hormonal milieu 703 
with the goal of inducing atrophy of the ectopic endometrium. This is generally achieved by inhibiting 704 
ovulation, reducing serum oestradiol levels, and suppressing uterine blood flows. To this aim, several 705 
drugs can be used, with a similar magnitude of effect, in term of pain relief, independently of the 706 
mechanism of action. Conversely, safety, tolerability, and cost differ. This has important practical 707 
implications, given that prolonged periods of treatment should be planned in symptomatic women not 708 
seeking pregnancy. In fact, all hormonal medications used for endometriosis are symptomatic and not 709 
curative. Moreover, hypothesising a selective cytoreductive effect on eutopic, but not eutopic 710 
endometrium appears currently unfounded. Medications for endometriosis can be categorised into low-711 
cost drugs, including OCs and most progestogens, and high cost drugs, including dienogest and GnRH 712 
agonists. As the individual response to different drugs is variable, a stepwise approach is suggested, 713 
starting with OCs or low-cost progestogens, and stepping up to high-cost drugs only in case of 714 
inefficacy or intolerance. According to the available evidence, about two thirds of symptomatic patients 715 
can be managed successfully with the former group of compounds, whereas the remaining third needs 716 
high-cost compounds or surgery. Oral contraceptives may be used in women with dysmenorrhoea as 717 
their main complaint, and when only superficial peritoneal implants or ovarian endometriomas < 5 cm 718 
are present, while progestogens should be preferred in women with severe deep dyspareunia and when 719 
deep infiltrating lesions are identified. 720 
721 
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Practice Points:  739 
• Available hormonal compounds for endometriosis are symptomatic and not curative 740 
• As symptom recurrence is the rule at drug discontinuation, long periods of treatments should be 741 
planned in women not seeking pregnancy 742 
• Medications for endometriosis have different safety and tolerability profiles and costs, but do 743 
not differ in terms of magnitude of the effect on pain 744 
• Low-dose oral contraceptives and low-cost progestogens should be considered first-line 745 
medications 746 
• High-cost compounds should be used only in women not responding or not tolerating first-line 747 
medications 748 
 749 
 750 
Research Agenda:  751 
• Non-teratogenic compounds that relieve pain without suppressing ovulation would allow 752 
treating also women seeking conception 753 
• Only drugs with a selective cytoreductive effect on ectopic but not eutopic endometrium would 754 
consent the modification of the natural history of endometriosis without compromising fertility 755 
• Epidemiological data are needed to define the potential long-term effects of prolonged use of 756 
different medications for endometriosis 757 
• Pragmatic trials including low-dose oral contraceptives or low-cost progestogens as active 758 
comparators are needed to define the incremental benefit of novel experimental drugs 759 
• Comparative effectiveness research on medications for endometriosis should include aspects of 760 
healthcare economic analysis such as quantification of opportunity costs 761 
 762 
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Table 1. Studies evaluating satisfaction with estrogen-progestogens for the treatment of symptomatic endometriosis (literature data, 1996–1153 
2017). 1154 
 1155 
Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stagea  
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction rateb 
Vercellini et al., 
1996 [18] 
RCT 80 Stage I n = 14; 
Stage II n = 30; 
Stage III n = 21; 
Stage IV n = 15 
DMPA 150 
mg i.m. 
injections/3 
months (n = 
40) 
Cyclic low-
dose 
monophasic 
OC (EE 0.02 
+DSG 0.15 
mg)/day + 
danazol 50 
mg/day for 21 
days of each 
28-day cycle (n 
= 40) 
12 months ITT Higher satisfaction 
with treatment in 
DMPA group (73% 
vs 58% in the OC 
group)  
Vercellini et al., 
2002 [19] 
RCT 90 Stage I n = 20; 
Stage II n = 19; 
Stage III n = 30; 
Stage IV n = 21 
Continuous 
low-dose 
monophasic 
OC (EE 0.02 + 
DSG 0.15 
mg)/day (n = 
45) 
Cyproterone 
acetate 12.5 
mg/day per os      
(n = 45) 
6 months ITT Slightly higher 
satisfaction with 
treatment in the 
cyproterone acetate 
group (73% vs 67% 
in the OC group) 
Vercellini et al., 
2003 [20] 
Prospective 
self-
controlled  
50c Women with 
histologically 
proven 
endometriosis 
(stage not 
specified)  
Continuous 
low-dose 
monophasic 
OC (EE 0.02 + 
DSG 0.15 
mg)/day per os 
NA 2 years ITT 80% of women were 
satisfied or very 
satisfied with 
continuous OC use 
Vercellini et al., 
2005 [21] 
RCT 90 Rectovaginal 
endometriosis 
Continuous 
low-dose 
monophasic 
OC (EE 0.01 + 
cyproterone 
acetate 3 
NETA 2.5 
mg/day per os 
(n = 45) 
12 months ITT Higher satisfaction 
with treatment in 
NETA group (73% vs 
62% in the OC group) 
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Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stagea  
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction rateb 
mg)/day (n 
=45) 
Vercellini et al., 
2010 [22] 
PPT 207 Stage I n = 56; 
Stage II n = 45; 
Stage III n = 52; 
Stage IV n = 54 
Rectovaginal 
endometriosis n = 
59  
 
Vaginal ring 
(EE 15 µg + 
etonogestrel 
120 µg) (n 
=123; 
rectovaginal 
endometriosis 
sub-group n = 
38) 
Transdermal 
patch (EE 20 
µg + 
norelgestromin 
150 µg) (n = 
84; 
rectovaginal 
endometriosis 
sub-group n = 
21) 
12 months ITT Higher satisfaction 
with treatments in 
vaginal ring group 
(71% vs 48% in the 
transdermal patch 
group). In the sub-
group of patients with 
rectovaginal 
endometriosis higher 
satisfaction rate in 
vaginal ring group 
(79% vs 57%) 
Cheewadhanaraks 
et al., 2012 [23] 
RCT 84 Stage I n = 23; 
Stage II n = 15; 
Stage III n = 13; 
Stage IV n = 33 
DMPA 150 
mg i.m. 
injections/3 
months (n = 
42) 
Continuous 
mid-dose 
monophasic 
OC (EE 0.03 
mg + gestodene 
0.075 mg)/day 
(n = 42) 
24 weeks ITT Similar satisfaction 
rates (93% in DMPA 
group vs 88% in OC 
group) 
Ferrari et al., 
2012 [24] 
Prospective 
non-
comparative 
26 Colorectal 
endometriosis 
(medium-low 
rectum nodules n 
= 4; proximal 
rectum, n = 14; 
recto-sigmoid 
junction/sigmoid, 
n = 8) 
Continuous 
low-dose 
monophasic 
OC (EE 15 µg 
+ gestodene 60 
µg)/day     
NA 12 months ITT 69% of the women 
were satisfied or very 
satisfied with 
continuous low-dose 
OC treatment 
Morelli et al., 
2013 [25] 
Retrospective 92 Post-operative 
administration in 
Continuous 
low-dose 
LNG-IUD (n = 
44) 
24 months Per-
protocol 
Higher satisfaction 
with treatment in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Vercellini et al., 55
Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stagea  
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction rateb 
women with 
histologically 
proven 
endometriosis  
 
multiphasic 
OC (DNG + 
E2V) /day (n = 
48) 
LNG-IUD users (98% 
vs 83% in OC users)d 
Leone Roberti 
Maggiore et al., 
2014 [26] 
PPT 143 Rectovaginal 
endometriosis 
DSG 75 
µg/day per os 
(n = 60)                
Vaginal ring       
(EE 15 µg + 
etonogestrel 
120 µg) (n = 
83) 
12 months ITT Higher patient 
satisfaction with 
treatment in DSG 
group (62% vs 36% 
in vaginal ring group) 
Morotti et al., 
2014 [27] 
PPT 144 Rectovaginal 
endometriosis 
DSG 75 
µg/day per os 
(n = 62) 
Cyclic low-
dose 
monophasic 
OC (EE 20 µg 
+ DSG 150 
µg)/day (n = 
82) 
6 months ITT Higher satisfaction 
with treatment in 
DSG group (61% vs 
38% in OC group) 
Harada et al., 
2017 [17] 
RCT 312e Not specified 
(most of the 
patients had a 
clinical diagnosis, 
with very few 
cases visually 
confirmed by 
laparoscopy) 
Low-dose 
monophasic 
OC (EE 0.02 + 
DRSP 3 mg)/ 
day, 
FlexibleMIB 
regimenf (n = 
130) 
Placebo (n = 
129) 
52 weeksg ITT Higher percentage of 
“very much 
satisfied/much 
satisfied/minimally 
satisfied” with 
treatment in OC 
group (75% vs 29% 
at week 24, and 83% 
vs 71% at week 52)h 
a
 According to the revised American Fertility Society classification [28]  1156 
b Unless otherwise specified, satisfaction with treatment was based on a five-category scale (very satisfied, satisfied, uncertain, dissatisfied, very 1157 
dissatisfied) 1158 
c
 Women with recurrent dysmenorrhea not responding to cyclic OC use  1159 
d Treatment satisfaction was defined by the percentage of women who successfully completed their treatment, without requiring suspension of the 1160 
assigned regimen 1161 
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e 53 women were randomized to an un-blinded reference arm (DNG 2 mg/day) in order to compare the vaginal bleeding pattern of FlexibleMIB 1162 
f The FlexibleMIB regimen consists of a repeat cycle of 120 consecutive days of active tablet followed by a 4-day tablet-free interval, either after the 1163 
120 days or after ≥3 consecutive days of bleeding and/or spotting between days 25 and 120 1164 
g After 24 weeks, placebo recipients were changed to FlexibleMIB 1165 
h
 Treatment satisfaction was assessed through a seven-category scale (very much satisfied, much satisfied, minimally satisfied, neither satisfied nor 1166 
dissatisfied, minimally dissatisfied, much dissatisfied, very much dissatisfied).   1167 
 1168 
DNG, dienogest; DRSP, drospirenone; DSG, desogestrel; E2V, estradiol valerate; EE, ethinyl-estradiol; ITT, intention-to-treat; NA, not applicable; 1169 
LNG-IUD, levonorgestrel-intrauterine device; NETA, norethisterone acetate; OC, oral contraceptive; PPT, patient preference trial; RCT, randomized 1170 
controlled trial 1171 
1172 
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Table 2. Hormonal activities of progestogens investigated for the treatment of endometriosis. Literature data, 2003-2015 [59-65]. 1173 
 1174 
 1175 
 1176 
 1177 
++ strong activity; + activity; +/- weak activity; - no activity 1178 
  1179 
1180 
 
Compound 
 
 
 
Progestogen 
activity 
 
 
Androgenic 
activity 
 
Anti-androgenic 
activity 
 
Glucocorticoid 
activity 
 
Anti-mineralcorticoid 
activity 
 
Half-life 
(h) 
 
Cyproterone acetate  
 
+ 
 
- 
 
++ 
 
+ 
 
- 
 
48-78.6 
 
Dienogest  
 
 
+ 
 
- 
 
+ 
 
- 
 
- 
 
 
6-12 
 
Levonorgestrel  
 
 
++ 
 
+ 
 
- 
 
- 
 
- 
 
9.9-26 
 
Medroxyprogesterone 
acetate  
 
++ 
 
± 
 
- 
 
+ 
 
- 
 
 
24 
 
Nomegestrol acetate  
 
 
+ 
 
- 
 
± 
 
 
- 
 
- 
 
50 
 
Norethisterone acetate  
 
++ 
 
+ 
 
- 
 
 
- 
 
- 
 
 
7-8 
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Table 3. Studies evaluating satisfaction with progestogens therapies for the treatment of symptomatic endometriosis (literature data, 1181 
1999–2017).a 1182 
 1183 
Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stageb 
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction ratec 
Vercellini et 
al., 1999 [92]  
Prospective 
non-
comparative  
pilot study  
20 Women with 
histologically 
proven 
endometriosis 
(stage not 
specified)  
LNG-IUD NA 12 months ITT 75% of women 
were satisfied or 
very satisfied with 
LNG-IUD 
treatment 
Vercellini et 
al., 2003 [49] 
RCT 40 Stage I n = 3; 
Stage II n = 6; 
Stage III n = 15; 
Stage IV n = 16 
LNG-IUD            
(n = 20) 
Expectant 
management 
after 
laparoscopic 
treatment of 
endometriotic 
lesions (n 
=20) 
12 months ITT Higher satisfaction 
with treatment in 
LNG-IUD group 
(75% vs 50% in the 
expectant 
management group) 
Lockhat et al., 
2004 [93] 
Prospective 
non-
comparative 
34 Stage I n = 5; 
Stage II n = 15; 
Stage III n = 6; 
Stage IV n = 0 
LNG-IUD NA 6 months Per 
protocol 
66% of women 
were satisfied or 
very satisfied with 
LNG-IUD 
treatment 
Ferrero et al., 
2009 [70] 
PPT 82 Rectovaginal 
endometriosis 
Letrozole 2.5 
mg + NETA 
2.5 mg/day per 
os (n = 41) 
NETA 2.5 
mg/day per os 
(n = 41) 
6 months ITT Higher satisfaction 
with NETA 
treatment only 
(63% vs 56% in 
letrozole + NETA 
group) 
Momoeda et 
al., 2009 [51] 
Prospective 
cohort study 
non-
comparative 
 
135 Ovarian 
endometriosis 
DNG 2 
mg/day per os 
NA 52 weeks Per 
protocol 
High satisfaction 
with treatment 
(89%)d 
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Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stageb 
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction ratec 
Walch et al., 
2009 [94] 
RCT 41 Stage I n = 11; 
Stage II n = 15; 
Stage III n = 7; 
Stage IV n = 8 
 
Etonogestrel 
68 mg implant 
(n = 21) 
DMPA 150 
mg i.m. 
injections/90 
days (n = 20) 
12 months ITT Comparable 
satisfaction with 
treatment (57% in 
the implant group 
vs 55% in the 
DMPA group) 
Ferrero et al., 
2010 [71] 
Prospective 
non-
comparative 
40 Colorectal 
endometriosis 
(sigmoid colon n = 
18; rectosigmoid 
junction n = 12; 
rectum n = 10)  
 
NETA 2.5 
mg/day per ose 
NA 12 months ITT 60% of the women 
were satisfied or 
very satisfied with 
NETA treatment 
Ferrero et al., 
2010 [72] 
Prospective 
non-
comparative 
6 Colorectal 
endometriosis 
(sigmoid colon n = 
2; rectosigmoid 
junction n = 2; 
rectum n = 2) 
Letrozole 2.5 
mg/day + 
NETA 2.5 
mg/day per os 
NA 6 months ITT 67% of the women 
were satisfied or 
very satisfied with 
NETA treatment 
Vercellini et 
al., 2012 [73] 
PPT 154 Stage III n = 64; 
Stage IV n = 90 
 
Rectovaginal 
endometriosis n = 
59  
NETA 2.5 
mg/day per os   
(n = 103; 
rectovaginal 
endometriosis 
sub-group n = 
35) 
Second-line 
laparoscopic 
excision of 
endometriotic 
lesions (n = 
51; 
rectovaginal 
endometriosis 
sub-group n = 
24) 
12 months ITT Higher satisfaction 
with treatment in 
NETA group (59% 
vs 43% in surgery 
group). In the sub-
group of patients 
with rectovaginal 
endometriosis 
similar satisfaction 
rate (54% in 
surgery group vs 
51% in NETA 
group) 
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Source Study design Number 
of 
patients 
enrolled 
Endometriosis 
location or stageb 
Study drug Comparator Treatment 
period 
Type of 
analysis 
Satisfaction ratec 
Morotti et al., 
2014 [95] 
Open-label 
prospective 
study non-
comparativef 
25 Rectovaginal 
endometriosis 
DNG 2 
mg/day per os  
NA 6 months ITT 52% of the women 
were satisfied or 
very satisfied after 
6 months of 
treatment with 
DNG 
Vercellini et 
al., 2016 [75] 
Before-after 
study 
90 Endometrioma n = 
104 
 
Deep 
endometriosis n = 
108 (rectovaginal 
endometriosis n = 
64; Douglas and 
parametria 
infiltrating lesions 
n = 39; bladder 
nodules n = 17; 
bowel nodules n = 
7)g 
 
DNG 2 
mg/day per os 
(n = 90) 
NETA 2.5 
mg/day per os 
(n = 90) 
6 months ITT Similar satisfaction 
with treatment 
(72% in DNG 
group vs 71% in 
NETA group). 
Comparable 
satisfaction in the 
sub-group of 
patients with 
rectovaginal 
endometriosis (68% 
in DNG group vs 
67% in NETA 
group) 
Morotti et al., 
2017 [76] 
Retrospective 
non-
comparative 
103 (61 
completed 
the 5-year 
follow-
up) 
Rectovaginal 
endometriosis 
NETA 2.5 
mg/day per ose 
NA 5 years ITT 41% of the women 
were satisfied or 
very satisfied with 
long term NETA 
treatment 
a  Seven studies comparing an estrogen-progestogen with a progestogen are included in Table 1 [Ref: 18,19,21,23,25-27]  1184 
b
 According to the revised American Fertility Society classification [28] 1185 
c Unless otherwise specified, satisfaction with treatment was based on a five-category scale (very satisfied, satisfied, uncertain, dissatisfied, very 1186 
dissatisfied) 1187 
d Patient satisfaction with treatment as determined by interview was classified into four categories (certainly willing to use again, prefer to use again, 1188 
hesitate to use again, and never willing to use again) 1189 
e In case of breakthrough bleeding, the dose of NETA was increased by 2.5 mg/day (maximum dose of 5 mg/day) 1190 
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f This study specifically selected patients with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months 1191 
of treatment with NETA 1192 
g44 women had more than one lesion                     1193 
DNG, dienogest; DSG; desogestrel; EE, ethinyl-estradiol; i.m., intramuscular; ITT, intention-to-treat; LNG-IUD, levonorgestrel-intrauterine device; 1194 
NETA, norethisterone acetate; NA, not applicable; OC, oral contraceptive; PPT, patient-preference trial                                                                                                                                                    1195 
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HIGHLIGHTS 
• Endometriosis is a chronic disorder requiring long-term adherence to treatment 
• Individual response to drugs is variable and a stepwise approach is suggested 
• Progestogens should be selected in case of deep lesions and severe deep dyspareunia 
 
